New drug combo shows promise for rare blood cancer
Disease control
Completed
This study tested a combination of two drugs, isatuximab and cemiplimab, in 37 adults with a rare blood cancer called NK/T-cell lymphoma that had come back or stopped responding to prior treatment. The goal was to see if the combination could shrink tumors and improve outcomes. T…
Phase: PHASE2 • Sponsor: Won Seog Kim • Aim: Disease control
Last updated May 18, 2026 12:01 UTC